Based on the present results indicating that SSTR2 is the dominant receptor (followed by sst5TMD4 and SSTR5 in both cell models), together with previous results demonstrating that sst5TMD4 can physically interact with SSTR2 and SSTR5 and alter their signaling [15], we next interrogated whether the overexpression of sst5TMD4 in GBM cells could be capable of modulating the expression levels of SSTR2 and SSTR5. The gene discussed is SSTR5; the disease is glioblastoma.